| Followers | 47 |
| Posts | 23586 |
| Boards Moderated | 0 |
| Alias Born | 09/16/2012 |
Tuesday, August 08, 2023 9:26:34 AM
Very positive press conference but let's stay real, folks.
"The data is a little tough to interpret in some ways"
"The data is a little bit messy but there's certainly signal there"
"The data is not as pristine as some would like".
"Almost doubled the proportion of patients driving over five years."
So, "Almost double" is not from 5 to 13%, as I've been saying, so the doc must believe 5 year is actually 7 or 8%.
Also doc say RI island likely has such a high rate of GBM because of the older population -60,70,80. We know older folks tend to pass faster. Keep in mind the average age of the L trial was 57.
Btw, This doc says the CEO told him the application for the FDA is in the works.
On the U:
DCVax-L® Press Conference at RI Hospital's Lifespan Cancer Institute. (Source: WRPI 12 News)
"The data is a little tough to interpret in some ways"
"The data is a little bit messy but there's certainly signal there"
"The data is not as pristine as some would like".
"Almost doubled the proportion of patients driving over five years."
So, "Almost double" is not from 5 to 13%, as I've been saying, so the doc must believe 5 year is actually 7 or 8%.
Also doc say RI island likely has such a high rate of GBM because of the older population -60,70,80. We know older folks tend to pass faster. Keep in mind the average age of the L trial was 57.
Btw, This doc says the CEO told him the application for the FDA is in the works.
On the U:
DCVax-L® Press Conference at RI Hospital's Lifespan Cancer Institute. (Source: WRPI 12 News)
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
